顯示具有 企業新研發 標籤的文章。 顯示所有文章
顯示具有 企業新研發 標籤的文章。 顯示所有文章

2026年9月12日 星期六

有些科學家在實驗室裡擁有「魔術手」。人工智能正在學習其中的奧秘。 (1/2)

 Recently The New Times reported the following:

Some Scientists Have ‘Magic Hands’ in the Lab. This A.I. Is Learning Why. (1/2)

Even the most adept researchers may not know exactly what they do to get successful results. An A.I. model is trying to figure it out by watching every move.

The NYT - By Carl Zimmer

Aug. 27, 2026

On a recent afternoon, scientists buzzed around a lab in Cambridge, Mass., performing experiments. Their equipment was standard: a lab hood for working with dangerous chemicals, an incubator for growing cells. Their procedures were identical to those in biology labs everywhere.

A closer look revealed some oddities, though. Along with lab coats and gloves, most of the scientists wore miniature cameras on headbands. Three additional cameras peered down at each work station from a shelf.

Lab notebooks were strangely absent. Instead, the scientists quietly narrated their work, murmuring into microphones. A team huddled at one end of the lab, inspecting videos of the experiments.

This was the real research taking place in this lab. With a system of sensors and software intended to capture science as it happens, down to the millisecond, scientists were training artificial intelligence models to recognize every object the scientists used and every action they performed.

The A.I. even composed its own narrative, describing every few seconds of video with sentences like, “The operator resuspends the pellet by pipetting it up and down 10 times.”

The technology is the creation of a start-up called Transfyr, which came out of stealth mode this week with $25 million in seed funding. The company is tackling an age-old challenge in science: the hidden factors that make some experiments succeed and others fail.

Failure can take many forms. Researchers may spend months preparing a line of engineered cells, only to have them mysteriously die along the way. A government Covid test seems to work in one lab, but fails to detect the virus when others use it.

A biotech company creates a promising new drug; when it hands off the protocol for large-scale production, suddenly it just doesn’t work.

“This is just an incredibly painful problem,” said Anna Marie Wagner, a co-founder of Transfyr. “There’s finger-pointing back and forth. Was your protocol wrong? Or did you screw something up? These are very, very expensive mistakes in terms of time, money, and lives.”

Success can be just as mysterious as failure. Some researchers consistently get experiments to work, earning befuddled admiration from colleagues. Scientists even have a special term for this gift: magic hands.

The idea may come as a surprise to people who don’t spend their lives in labs. Science is not supposed to be magic.

When scientists carry out experiments, they keep careful records, both in lab notebooks and later in published scientific papers. Other researchers use that information to repeat the experiment.

But every scientist discovers sooner or later that essential knowledge is not necessarily written down.

“A protocol is a recipe,” said Jonathan Livny, a senior research scientist at the Broad Institute who has collaborated with Transfyr. “You can give somebody a recipe, and it’s not going to make them a great chef.”

Like apprentice chefs, scientists spend years in training, shadowing experts, asking questions and trying out procedures for themselves.

To make an experiment work, they may have to make thousands of minor decisions over the course of a day. A tube needs to be shaken — let it whir on a vibrating platform, or just flick it back and forth by hand?

“The really good people sometimes don’t know why they’re that good,” Dr. Livny said. “They don’t remember the 20 times they did something another way and it failed. They’ve blocked all that sadness out.”

In the 1960s, the Hungarian chemist and philosopher Michael Polyani gave this mysterious expertise a name: tacit knowledge. “We know more than we can tell,” he liked to say.

Scientists have generally come to agree with Polanyi that tacit knowledge is an essential part of research. But it can also slow down progress.

In theory, science moves forward as researchers build on previous work. When a new study comes out, other scientists will attempt to replicate the work. If the original result was correct, a replication ought to produce the same results.

Surprisingly often, it doesn’t. And tacit knowledge is part of the problem. Scientists can’t know exactly how to replicate a study simply by reading about it.

(to be continued)

Translation

有些科學家在實驗室裡擁有「魔術手」。人工智能正在學習其中的奧秘。 (1/2)

即使是最熟練的研究人員,也可能不完全清楚自己是如何取得成功的。一款人工智能模型正試圖透過觀察他們的每一個動作來找出答案

最近一個下午,在麻薩諸塞州劍橋市的一間實驗室裡,科學家們忙著進行各種實驗。他們的設備都很標準:用於處理危險化學品的通風櫃,以及用於培養細胞的培養箱。他們的實驗流程也與世界各地生物實驗室的流程完全相同。

然而,仔細觀察後卻發現了一些奇怪之處。除了實驗服和手套,大多數科學家頭上都戴著微型攝影機。另外三個攝影機則從架上俯視著每個工作台。

奇怪的是,實驗紀錄簿不見了。取而代之的是,科學家們對著麥克風低聲講述他們的工作。一個小組聚集在實驗室的一端,正在查看實驗的錄影。

這才是這個實驗室真正進行的研究。科學家利用一套旨在精確到毫秒地捕捉科學過程的感測器和軟件系統,訓練人工智能模型來識別他們使用的每個物體和執行的每一個動作。

人工智能甚至能夠產生自己的敘述,用諸如每隔幾秒鐘用「操作員用移液器上下吸取10次,使沉澱物重新懸浮」之類的句子來描述影片。

這項技術出自一家名為 Transfyr 的新創公司,該公司本週結束了隱密地運營,並獲得了2,500萬美元的種子輪融資。該公司正在攻克科學界一個長久以來的難題:導致某些實驗成功而另一些實驗失敗的隱藏因素。

失敗的形式多種多樣。研究人員可能花費數月時間建構出一組細胞,卻發現這些細胞在建構過程中神祕死亡。政府研發的一種新冠病毒檢測方法在一個實驗室似乎有效,但在其他實驗室卻無法檢測到病毒。

一家生技公司研發出一種很有前景的新藥;當它把生產方案交給大規模生產團隊時,突然發現這種藥根本不起作用。

Transfyr 的聯合創始人 Anna Marie Wagner 說: “這真是個令人無比頭疼的問題”; “大家互相指責。是不是你的流程錯了?還是你哪裡搞砸了?這些錯誤在時間、金錢和生命方面都代價極其高昂。”

成功和失敗一樣神秘莫測。有些研究人員總是能成功完成實驗,贏得同事們既困惑又欽佩的讚嘆。科學家甚至給這種天賦取了個專門的詞:魔術之手。

對於那些不常待在實驗室的人來說,這種說法或許會讓他們感到驚訝。科學不應該是魔術。

科學家在進行實驗時,會仔細記錄實驗過程,既會記在實驗筆記裡,也會在之後發表的科學論文中加以闡述。其他研究人員會利用這些資訊來重複實驗。

但每位科學家遲早都會發現,關鍵的知識並非總是會被記錄下來的。

曾與 Transfyr 公司合作的博德研究所 高級研究科學家 Jonathan Livny 說道:「實驗方案就像食譜」; 「你可以給別人一份食譜,但這並不能讓他們成為一位偉大的廚師」。

就像學徒廚師一樣,科學家需要花費數年時間進行培訓,跟隨專家學習,不斷提問,並親自嘗試各種實驗步驟。

為了讓實驗成功,他們可能一天之內要做出成千上萬個細微的決定。例如,當需要搖晃試管 - 是讓它在振動平台上旋轉,還是用手輕輕地搖動它?

Livny 博士說: 「真正優秀的人有時甚至不知道自己為什麼如此優秀」; 「他們不記得自己曾經嘗試過其他方法卻失敗了20次。他們已經把那些失敗感都隔掉了」。

在1960年代,匈牙利化學家兼哲學家 Michael Polyani 將這種神秘的專業知識命名為「融會知識」。他常說: 「我們知道的比我們能表達出來的要多」。

科學家普遍認同 Polanyi 的觀點,即融會知識是研究的重要組成部分。但它也可能阻礙研究進展。

理論上,科學的進步源自於研究者在前人工作的基礎上不斷拓展。當一項新研究發表時,其他科學家會嘗試重複這項研究。如果最初的結果是正確的,那麼重複實驗應該會得出相同的結果。

然而,令人驚訝的是,能得出相同的結果不是經常發生。而融會知識正是問題所在。科學家無法僅憑閱讀就準確地知道如何重複一項研究。

(待續)

2026年5月9日 星期六

兩種藥物為致命胰臟癌的治療帶來希望 (2/2)

Recently the New York Times reported the following:

Two Drugs Stir Hope for Treatment of Deadly Pancreatic Cancer (2/2)

In separate small clinical trials, two treatments showed promise that they could help patients with one of the most dire diagnoses in oncology.

The NYT - By Rebecca Robbins and Gina Kolata

April 21, 2026

(continue)

Revolution, based near San Francisco, said that it was planning to seek regulatory approval soon for the treatment, which the Food and Drug Administration has already designated for a fast-track review.

The other promising treatment involved a personalized vaccine using mRNA technology. Unlike vaccines for infectious diseases, which aim to prevent people from contracting an illness, there is hope that vaccines could be used to treat cancer that has already been diagnosed, though the approach is not widely used for most cancers.

In San Diego this week, researchers reported that in a small safety study, seven of eight patients whose immune systems responded to the treatment were alive up to six years after receiving the last treatment, compared with just two of out [sic] eight of those whose immune systems did not respond.

Phase 1 studies like this one are not designed to assess whether a treatment is effective, only whether it is safe. The treatment is being developed by BioNTech and Roche’s Genentech unit.

The technology used in the vaccine, known as messenger RNA, or mRNA, is best known for its use in Covid vaccines. It instructs the body to produce a fragment of a virus that then sets off an immune response.

Under Health Secretary Robert F. Kennedy Jr., the Trump administration has made a series of funding and policy changes that are hostile to the technology.

Patients diagnosed with pancreatic cancer fare far worse than people with other cancers, like some of the blood or breast. In those other forms of cancer, significant treatment advances in recent years have turned once devastating diagnoses into manageable chronic illnesses for large numbers of patients.

Pancreatic cancer is different from many other cancers. It is often caught very late, when the disease has already spread widely, because it often presents no early symptoms. Patients often realize something is wrong only when they suddenly lose weight and become jaundiced. And treatment approaches like immunotherapy that have transformed the outlook for other cancers have not worked for that of the pancreas.

Translation

兩種藥物為致命胰臟癌的治療帶來希望 (2/2)

在兩項獨立的小型臨床試驗中,兩種療法展現出治療胰臟癌的潛力,這種癌症是腫瘤學中最致命的疾病之一

(繼續)

總部位於舊金山附近的Revolution公司表示,他們計劃很快向監管機構申請批准該療法。美國食品藥物管理局(FDA)已將它列入快速審批通道。

另一種有前景的療法是一種利用mRNA技術的個人化疫苗。它與旨在預防疾病的傳染病疫苗不同,人們希望這種疫苗能夠用於治療已確診的癌症,儘管這種方法目前尚未廣泛應用於大多數癌症的治療。

本週在聖地牙哥,研究人員報告稱,在一項小型安全性研究中,8名免疫系統對治療有反應的患者中有7名在接受最後一次治療後存活長達6年,而8名免疫系統無反應的患者中只有2名存活。

像這樣的一期研究並非旨在評估治療的有效性,而僅評估其安全性。此療法由BioNTech和羅氏旗下的Genentech單位共同研發。

此疫苗採用的技術稱為信使RNA(mRNA),最廣為人知的應用是新冠疫苗。它能引導人體產生病毒片段,進而引發免疫反應。

在 Robert F. Kennedy Jr. 擔任衛生部長期間,特朗普政府對這項技術進行了一系列不利的資金和政策調整。

胰臟癌患者的處境遠差於其他癌症患者,例如某些血液癌症或乳癌患者。在其他類型的癌症中,近年來治療技術的顯著進步已將曾經令人絕望的大量患者被診斷為可控制的慢性疾病。

胰臟癌與其他許多癌症不同。由於胰臟癌早期通常沒有症狀,因此往往發現時已是晚期,癌細胞已廣泛擴散。患者往往只有在突然體重下降和出現黃疸時才意識到身體出了問題。類似免疫療法等現已改變其他癌症的治療前景,但對胰臟癌卻仍然無效。

So, two separated test treatments that are carried out in clinical trials are raising hopes for patients with pancreatic cancer. Currently, patients diagnosed with pancreatic cancer fare far worse than people with other cancers. In those other forms of cancer, significant treatment advances in recent years have turned once devastating diagnoses into manageable chronic illnesses. Apparently,  new drugs are offering new hope to many patients. This is good news to everyone.

2026年5月8日 星期五

兩種藥物為致命胰臟癌的治療帶來希望(1/2)

Recently the New York Times reported the following:

(Source: The NYT)

Two Drugs Stir Hope for Treatment of Deadly Pancreatic Cancer (1/2)

In separate small clinical trials, two treatments showed promise that they could help patients with one of the most dire diagnoses in oncology.

The NYT - By Rebecca Robbins and Gina Kolata

April 21, 2026

Two treatments being tested in clinical trials are raising hopes for patients with pancreatic cancer, which has long been one of the most dire diagnoses in oncology.

Researchers presented the promising data this week at a cancer conference in San Diego. The data was collected from a small number of patients and has not yet been published in a medical journal or reviewed by regulators. Neither drug has been approved for use.

Cancer of the pancreas, the gland buried deep in the abdomen that is involved in digestion and regulates blood sugar, kills more than 50,000 Americans each year, accounting for about 8 percent of cancer deaths in the United States. Many patients die within a year of diagnosis, and only 13 percent of people live for five years after being diagnosed.

There are few treatment options, and those that are available often do little to help, which is why the new drugs are generating so much excitement.

“We are having to tell ourselves that this is in fact unprecedented,” said Dr. Robert Vonderheide, director of the Abramson Cancer Center of the University of Pennsylvania, who was not involved in the new research.

One of the experimental drugs, daraxonrasib, doubled diagnosed patients’ life expectancy, giving them over 13 months, compared to less than seven months for those who received chemotherapy in a late-stage clinical trial, according to Revolution Medicines, the company developing the drug.

A gain of six months of life is virtually unheard-of in the field. The company also said the drug’s side effects were “manageable.”

“The statistic that caught everyone’s eye was a doubling of overall survival,” said Dr. Vonderheide, who is also president-elect of the American Association for Cancer Research, the group of oncologists and scientists that is hosting the meeting in San Diego this week. “This is a patient population that has very limited options. To see that effect with a side-effect profile that is manageable unleashed a lot of excitement in the field.”

Researchers plan to present the data next month at a cancer conference in Chicago. In San Diego this week, researchers presented data from earlier stage testing of the drug that involved a few dozen patients. Many patients reported side effects like rash, diarrhea, fatigue and nausea. No patients died because of the treatment.

In a recent interview with The New York Times, former Senator Ben Sasse, a Republican from Nebraska, who late last year disclosed his terminal pancreatic cancer diagnosis, said he had been receiving that drug in a clinical trial.

He said he had been told in December that he had three or four months to live, but that the drug had shrunk his tumors and allowed him to reduce his reliance on pain medication. He had a rash on his face that he attributed to a side effect from the drug.

(to be continued)

Translation

兩種藥物為致命胰臟癌的治療帶來希望(1/2)

在兩項獨立的小型臨床試驗中,兩種療法展現出治療胰臟癌的潛力,這種癌症是腫瘤學中最致命的疾病之一。

兩種正在進行臨床試驗的療法為胰臟癌患者帶來了希望,胰臟癌長期以來都是腫瘤學中最致命的疾病之一。

研究人員本週在聖地牙哥舉行的癌症會議上公佈了這些令人鼓舞的數據。這些數據來自少量患者,尚未在醫學期刊上發表,也未經監管機構審查。這兩種藥物均未獲準使用。

胰臟癌是位於腹部深處的一個腺體,負責消化和調節血糖。每年,胰臟癌導致超過5萬美國人死亡,約佔美國癌症死亡人數的8%。許多患者在確診後一年內死亡,僅有13%的患者在確診後能存活五年。

治療選擇寥寥無幾,現有的治療手段往往收效甚微,因此,這些新藥的出現令人振奮。

未參與這項新研究的賓州大學艾布拉姆森癌症中心主任Robert Vonderheide博士說道:「我們不得不承認,這確實是前所未有的」。

根據研發該藥物的Revolution Medicines公司稱,其中一種名為daraxonrasib的實驗性藥物,使確診患者的預期壽命延長了一倍,超過13個月,而相較之下,在後期臨床試驗中接受化療的患者,其存活期不到七個月。

在癌症治療領域,延長六個月的生命幾乎是聞所未聞。該公司還表示,該藥物的副作用「可控」。

Vonderheide博士說: 「最引人注目的數據是總生存期翻了一番」。他同時也是美國癌症研究協會的候任主席,該協會由腫瘤學家和科學家組成,本週在聖地牙哥舉辦了這場會議。 「這類患者的治療選擇非常有限。這種藥物在副作用可控的情況下還能取得如此顯著的療效,在業內引起了極大的鼓舞。”

研究人員計劃下個月在芝加哥舉行的癌症會議上公佈這些數據。本週在聖地牙哥,研究人員展示了該藥物早期階段試驗的數據,該試驗涉及數十名患者。許多患者報告了皮疹、腹瀉、疲勞和噁心等副作用。沒有患者因治療而死亡。

內布拉斯加州共和黨前參議員Ben Sasse在最近接受《紐約時報》採訪時表示,他曾參與一項臨床試驗,並接受過該藥物的治療。Sasse於去年年底公開了他被診斷出患有晚期胰腺癌。

他說,去年12月醫生告訴他,他只有三、四個月的壽命了,但這種藥縮小了他的腫瘤,讓他減少了對止痛藥的依賴。他臉上長了皮疹,他認為這是藥物的副作用。

(待續)

2025年11月1日 星期六

為什麼鑽石是電腦晶片新的寵兒 (2/2)

Recently the New York Times reported the following:

Why Diamonds Are a Computer Chip’s New Best Friend (2/2)

Data centers squander vast amounts of electricity, most of it as heat. The physical properties of diamond offer a potential solution, researchers say.

The NYT - By Amos Zeeberg

Oct. 8, 2025

(continue)

After making the diamond disks, which are four inches wide, the company says that it uses patented techniques to smooth the diamond so flat that there is no defect larger than one atom above or below the entire surface of the wafer. Customers can then attach the flat diamond wafer to the bottom of their silicon-based chips.

The diamond layers “dissipate chip hot spots entirely,” Mr. Roscheisen said. “They’re effectively gone.”

“This approach could dramatically lower thermal resistance,” said Evelyn Wang, a mechanical engineer at M.I.T., but she noted that the technology has not yet been proven commercially.

Element Six, which is owned by De Beers, the diamond company, has long manufactured diamonds for industrial use and for cooling the chips used in powerful radio-communication devices, including communication satellites. Now it is marketing its diamonds for cooling computer chips.

“The thermal demands of next-generation A.I. and high-performance computing devices are driving renewed interest in advanced cooling solutions,” said Bruce Bolliger, the head of business development.

In January, the company announced a new material, a hybrid of diamond and copper intended to channel heat better than copper alone while being cheaper than diamond. “Copper-diamond composite provides an optimal thermal management solution” for powerful new chips, Mr. Bolliger said, which could let them run faster, increase their lifetimes and decrease the cooling costs for data centers.

Srabanti Chowdhury, an electrical engineer at Stanford University, is using diamond to explore a new, more powerful kind of computer chip.

Historically, the main way to increase the speed of chips was to shrink transistors and cram more of them together on a flat silicon wafer. But chipmakers are running up against physical limits to how small they can make transistors. Researchers have tried to solve the problem by layering transistors on top of one another, but multiple layers produce even more heat.

Dr. Chowdhury’s group sought to siphon off heat using diamond layers made of many crystals, which are easier to manufacture than single crystals. But they faced obstacles. Usually in polycrystalline diamond layers, the crystals are oriented vertically and not so good at moving heat horizontally, which is the major requirement in chips, because chips are flat and wide.

Moreover, diamond is typically grown at temperatures over 1,300 degrees Fahrenheit, but that is far too hot for the silicon that serves as the chip’s foundation. When Dr. Chowdhury’s group tried to deposit diamond on silicon at a lower temperature, they had trouble getting the crystals to form correctly. “Every crystal that likes to grow at high temperatures, there are problems when you grow it at low temperatures,” she said.

The research is partly funded by DARPA, the research agency of the U.S. Department of Defense. “Pairing this low-temperature technology with other heat-removal approaches could unlock compute capabilities that aren’t currently feasible,” said Yogendra Joshi, a mechanical engineer at the Georgia Institute of Technology and a program manager at DARPA.

Dr. Chowdhury said that she and other researchers are trying to address a challenge that is both old and new. “The problem of heat was already there, but now that the growth really came with A.I., it’s like a hockey stick — we see this problem growing very big,” she said. “I have not seen anything that was so important so quickly.”

Translation

為什麼鑽石是電腦晶片新的寵兒(2/2)

數據中心浪費了大量電力,其中大部分轉化為熱。研究人員表示,鑽石的物理特性提供了一個潛在的解決方案。

(繼續)

該公司表示,在製造出4英寸寬的鑽石圓盤後,他們使用專利技術將鑽石打磨得非常平整,使得晶圓整個表面上下都不存在大於一個原子的缺陷。客戶隨後可以將平坦的鑽石晶圓貼附到矽基晶片的底部。

Roscheisen先生表示,鑽石層 “可以完全消散晶片熱點”; “實際上它們已經消失了。”

麻省理工學院機械工程師Evelyn Wang表示:「這種方法可以顯著降低熱阻。」但她指出,這項技術尚未經過商業驗證。

Element Six隸屬於鑽石公司De Beers,長期以來一直致力於生產用於工業用途的鑽石,以及用於冷卻包括通訊衛星在內的強大無線電通訊設備晶片的鑽石。現在,該公司正在推廣用於冷卻電腦晶片的鑽石。

業務發展主管Bruce Bolliger說:「下一代人工智能和高效能運算設備的散熱需求,正在重新激發人們對先進冷卻解決方案的興趣」。

今年1月,該公司宣布了一種新材料 - 鑽石和銅的混合物,旨在比單純使用銅更好地傳導熱量,同時價格低於鑽石。Bolliger先生表示,“銅-鑽石複合材料為強大的新型晶片提供了最佳的熱管理解決方案”,這可以提高晶片的運行速度、延長其使用壽命,並降低數據中心的冷卻成本。

史丹佛大學電氣工程師 Srabanti Chowdhury 正在利用鑽石探索一種新型、更強大的電腦晶片。

從歷史上看,提高晶片速度的主要方法是縮小電晶體尺寸,並將更多電晶體塞進平坦的矽晶片上。然而,晶片製造商正面臨可以把晶體管做得最小的物理極限。研究人員試圖透過將晶體管層疊起來來解決這個問題,但多層電晶體會產生更多熱量。

Chowdhury 博士的團隊試圖利用多晶體構成的鑽石層來抽取熱,因為這比單晶體更容易製造。但他們面臨重重障礙。通常情況下,多晶鑽石層中的晶體是垂直取向的,不太能作出橫向地散熱,而橫向散熱是晶片的主要要求,因為晶片是又平又寬。

此外,鑽石通常在超過700攝氏度(1300華氏度)的溫度下生長,但對於作為晶片基礎的矽來說,這個溫度太高了。當Chowdhury博士的團隊嘗試在較低溫度下將鑽石沉積在矽上時,他們遇到了晶體無法正確形成的問題。她說: 「所有喜歡在高溫下生長的晶體,在低溫下生長都會出現問題」。

這項研究的部分資金由美國國防部高級研究計劃局(DARPA)提供。佐治亞理工學院機械工程師、DARPA專案經理Yogendra Joshi表示:“將這項低溫技術與其他散熱方法相結合,可以釋放目前不可能的計算能力。”

Chowdhury博士表示,她和其他研究人員正在努力應對一個既古老又新穎的挑戰。她說: 「散熱問題早已存在,但現在隨著人工智能的真正發展,它就像一根曲棍球棒 - 我們看到這個問題變得越來越大」。 「我從未見過任何事物如此重要如此急速」。

 So, with tech companies racing to build more data centers to house servers that run the latest A.I. models, the amount of electricity these facilities consume is skyrocketing. But most of that electricity doesn’t power computing at all but is spilling out as heat.  Engineers have been exploring how to make a thin layer of heat-dissipating diamond and attach it to the back of the silicon wafers on which chips are built. One selling point of this approach is that its thin diamond layers are made of single crystals, which are better at dissipating heat than arrays of crystals are. Apparently, if the new approach is commercially viable, it will be a groundbreaking event.

2025年10月30日 星期四

為什麼鑽石是電腦晶片新的寵兒(1/2)

Recently the New York Times reported the following:

Why Diamonds Are a Computer Chip’s New Best Friend (1/2)

Data centers squander vast amounts of electricity, most of it as heat. The physical properties of diamond offer a potential solution, researchers say.

The NYT - By Amos Zeeberg

Oct. 8, 2025

With tech companies racing to build more data centers housing servers that run the latest A.I. models, the amount of electricity these facilities consume is skyrocketing. But most of that electricity doesn’t power computing at all. It is squandered in the crudest way: as heat, spilling out of every one of the hundreds of billions of transistors in a modern chip.

 “The dirty secret in chips is that more than half of all energy is wasted as leakage current at the transistor level,” said R. Martin Roscheisen, an electrical engineer and entrepreneur at Diamond Foundry, a company in South San Francisco that manufactures specialized diamonds for use in electronics.

This heat is a great waste of energy that significantly shortens a chip’s life and makes it run less efficiently, generating still more wasteful heat. Consequently, one of the critical tasks in data centers is keeping the temperature of servers down so they can run smoothly.

Mr. Roscheisen is one of many engineers developing ways to embed tiny pieces of synthetic diamond, of all things, into chips to keep them cool. Diamond, in addition to being the hardest known material, is also exceptionally good at moving heat from place to place.

“Most people do not realize that diamond has the best heat-conduction properties of any material,” said Paul May, a physical chemist at the University of Bristol in England. He added that diamond conducts heat several times faster than copper, a material often used in heat sinks for chips.

The high thermal conductivity of diamond arises from the same property that makes it so hard: Each carbon atom is bonded strongly to four neighbors, with no weak link in any direction. Those strong bonds are efficient at carrying the vibrations that move heat through a crystal.

“High-end electronics can already be bought that use diamond heat-spreaders,” Dr. May said. “Within a few years, even the processor in your home PC or mobile phone will probably be attached to a diamond heat-spreader.”

In recent years, Mr. Roscheisen’s company has been exploring how to make a thin layer of heat-dissipating diamond and attach it to the back of the silicon wafers on which chips are built. One selling point of this approach is that its thin diamond layers are made of single crystals, which are better at dissipating heat than arrays of crystals are. But such thin layers are harder to make, and consequently more expensive.

The company manufactures diamonds by making a very hot gas, or plasma, rich in carbon and coaxing it to deposit carbon atoms in precisely the right configuration. A key step, according to the company, is tricking each diamond to begin crystallizing as though it were growing atop a layer of existing, perfectly ordered diamond.

This effectively shows the new carbon atoms how to fit together. Proceeding without that instruction, the company’s website states, “is like multiple people trying to tile a floor from different ends of a room without using a template: They would meet somewhere in the middle without fitting” into a single, unified crystal.

(to be continued)

Translation

為什麼鑽石是電腦晶片新的寵兒(1/2)

數據中心浪費了大量電力,其中大部分以熱量的形式釋放。研究人員表示,鑽石的物理特性提供了一個潛在的解決方案。

隨著科技公司競相建造更多數據中心用於收容運行最新人工智能模型的伺服器,這些設施的耗電量正在飆升。但這些電力大部分根本沒有用來運算。它們以最原始的方式浪費:以熱量的形式,從現代晶片中數千億個電晶體中散發出來。

南舊金山一家專門生產電子產品用的鑽石製造公司 - Diamond Foundry的電氣工程師兼企業家R. Martin Roscheisen說道: 「晶片中一個不光彩的秘密是,超過一半的能量在晶體管層面以漏電流的形式被浪廢了」。

這些熱量會大大浪費能源,顯著縮短晶片壽命,降低晶片運作效率,並產生出更多浪費的熱能。因此,數據中心的關鍵任務之一就是降低伺服器的溫度,以確保其平穩運作。

Roscheisen先生是眾多工程師之一,正在開發將微小的人造鑽石嵌入晶片, 令人驚訝地, 以保持晶片冷卻的方法。鑽石不僅是已知最堅硬的材料,而且還非常善於將熱量從一個地方轉移到另一個地方。

英國布里斯託大學的物理化學家Paul May說:「大多數人沒有意識到,鑽石的導熱性能是所有材料中最好的」。他又補充說,鑽石的導熱速度是銅的數倍,而銅是晶片散熱器中常用的材料。

鑽石的高導熱性源自於其堅硬的特性:每個碳原子都與四個相鄰的碳原子牢固地鍵合,在任何方向上都沒有薄弱環節。這些牢固的鍵能夠有效地傳遞熱量在晶體中移動的振動。

May博士說: 「現在高端電子產品已經可以買到使用鑽石散熱器了」; 「幾年之內,就連家用電腦或手機的處理器也很可能連接到鑽石散熱器上」。

近年來,Roscheisen先生的公司一直在探索如何製造一層薄薄的散熱鑽石,並將其附著在建造晶片的矽晶圓背面。這種方法的一大賣點是,其薄鑽石層由單晶構成,比晶體陣列散熱效果更好。但這種薄層製造起來更困難,因此成本也更高。

該公司透過製造富含碳的高溫氣體或等離子體,誘導其精確地沉積碳原子到一個恰好的正確組態來製造鑽石。根據該公司介紹,關鍵步驟是誘導每顆鑽石開始結晶,就像它們生長在一層現有的、排列完整的鑽石之上一樣。

其真正結果是提點了新碳原子如何組合在一起。該公司網站稱,如果不按照該指示去進行,「就像多人不使用模板而試圖去從房間的不同起點鋪設地板:他們會在中間某個地方相遇,而無法拼合」成一個單一, 完整的晶體。

(待續)

2025年8月20日 星期三

經過 Sam Altman 多年的炒作宣傳,OpenAI 的 GPT-5 終於正式上線並免費向所有人開放 - 以下是它的功能

 Recently Yahoo News on-line picked up the following:

OpenAI's GPT-5 is live and free for all after years of hype by Sam Altman. Here's what it can do.

Business Insider - Lakshmi Varanasi,Brent D. Griffiths,Jyoti Mann,Robert Scammell

Updated Thu, August 7, 2025 at 11:40 a.m. PDT·3 min read

After weeks of relentless hype, GPT-5 is finally here.

OpenAI officially released the highly anticipated new model on Thursday. It's the latest version of ChatGPT, the company's flagship chatbot, and the most widely used AI model on the market.

OpenAI CEO Sam Altman called it a "major upgrade" and "a significant step along the path of AGI" in a conference call with journalists on Wednesday. He said that after using GPT-5, going back to GPT-4 was "miserable."

OpenAI says the model will be available for free for everyone and that users will no longer need to switch between previous models for different tasks. GPT-5 will switch automatically, the company said, depending on the kind of request and its complexity. GPT-5 will be available in standard, mini, and nano versions. Paid users will have higher usage limits.

Altman said GPT-5 was also the company's fastest model yet.

"One of the things I had been pushing the team on was like, 'Hey, we need to make it way, way faster,'" Altman said. "And I now have this experience of like, 'Are you sure you thought enough?'"

The team said GPT-5 will have improved capabilities for vibe coding, the latest craze in Silicon Valley.

OpenAI has been teasing this next iteration of ChatGPT for over a year, but has ramped up the chatter in the last few days and weeks. On Sunday, Altman shared a screenshot of GPT-5 on X, asking the model to recommend the "most thought-provoking" TV show about AI.

In July, Altman said that "GPT-5 is smarter than us in almost every way." Speaking to podcaster Theo Von, Altman said he asked GPT-5 a question he "didn't quite understand" and it "answered it perfectly," making him feel "useless relative to the AI."

The OpenAI CEO also likened GPT-5's development to the Manhattan Project, the US government's effort to build the atomic bomb during World War II, and said that it made him feel nervous.

"There are moments in the history of science, where you have a group of scientists look at their creation and just say, you know: 'What have we done?'" Altman said.

OpenAI's last notable model launch was GPT-4.5 in February, which Altman described at the time as "the first model that feels like talking to a thoughtful person."

The release of GPT-5 has faced several delays, with the timeline shifting from mid-2024 to mid-2025, to August.

During that time, the number of ChatGPT users has continued to grow. In April, Altman said ChatGPT had 500 million weekly active users. OpenAI said on Thursday that ChatGPT is now on track to hit 700 million weekly active users "this week."

Translation

經過 Sam Altman 多年的炒作宣傳,OpenAI 的 GPT-5 終於正式上線並免費向所有人開放 - 以下是它的功能

經過數週的持續宣傳,GPT-5 終於來了。

OpenAI 於週四正式發布了備受期待的新模型。這是該公司旗艦聊天機器人 ChatGPT 的最新版本,也是市場上最廣泛使用的 AI 模型。

OpenAI 執行長 Sam Altman 在周三與記者的電話會議上稱其為一次「重大升級」和「在通用人工智慧 (AGI) 道路上邁出的重要一步」。他表示,在使用 GPT-5 之後,回到 GPT-4 感覺「很悲」。

OpenAI 表示,該模型將免費向所有人開放,用戶無需再在不同任務之間切換先前的模型。該公司表示,GPT-5 將根據請求的類型及其複雜程度自動切換。 GPT-5 將提供標準版、迷你版和奈米版。付費用戶將有更少的使用限制。

Altman 表示,GPT-5 也是該公司迄今為止速度最快的模型。

Altman 說: 「我一直督促團隊的事情之一是,『嘿,我們需要令它大幅提速』」; 「我現在有類似這樣的經歷:’您確定認為已經夠了嗎?’ 」

團隊表示,GPT-5 將改善對氛圍編碼(矽谷最新熱潮)的功能。

OpenAI 一年多來一直在預告 ChatGPT 的下一代版本,但在最近幾天和幾週內,它的熱度有所提升。週日,Altman 在 X 上分享了 GPT-5 的截圖,要求該模型推薦一部「最發人深省」的 AI 電視節目。

今年 7 月,Altman 表示「GPT-5 幾乎在所有方面都比我們聰明」。Altman 在接受播客 Theo Von 採訪時表示他向 GPT-5 提出了一個 “不太理解”的問題,而 GPT-5 “完美地回答了”,這讓他覺得自己 “在相比 AI 之下一無是處”。

這位 OpenAI 執行長也將 GPT-5 的開發比作曼哈頓計劃(二戰期間美國政府為製造原子彈所做的努力),並表示這讓他感到緊張。

Altman 說: 「在科學史上,總有那麼一刻,一群科學家看著他們的成果,然後問:『我們做了什麼?』」。

OpenAI 上一次值得關注的模型發佈是 2 月份的 GPT-4.5,Altman 當時將其描述為「第一個感覺像在與一位深思熟慮的人交談的模型」。

GPT-5 的發布經歷了幾次延期,時間表從 2024 年中期推遲到 2025 年中期,最終推遲到 8 月。

在此期間,ChatGPT 的用戶數量持續增長。今年 4 月,Altman 表示 ChatGPT 的每周活躍用戶已達 5 億。 OpenAI 週四表示,ChatGPT 預計將在「本週」達到 7 億每週活躍用戶。

              So, OpenAI has officially released the highly anticipated new model. Recently, the number of ChatGPT users continues to grow. In April, Altman said ChatGPT had 500 million weekly active users. Recently, it is on track to hit 700 million weekly active users. Apparently, ChatGPT is gaining popularity in these days.

Note:

1. Vibe coding (氛圍編碼)is an artificial intelligence-assisted software development style popularized by Andrej Karpathy in February 2025.The term was listed in the Merriam-Webster Dictionary the following month as a "slang & trending" term. It describes a chatbot-based approach to creating software where the developer describes a project or task to a large language model (LLM), which generates code based on the prompt. Unlike traditional AI-assisted coding or pair programming, the human developer avoids micromanaging the code, accepts AI-suggested completions liberally, and focuses more on iterative experimentation than code correctness or structure. (Wikipedia)

2025年3月23日 星期日

一家名不見經傳的中國公司研發出一種藥物,打敗了全球最暢銷的藥物(1/2)

 Recently Yahoo News on-line picked up the following:

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine (1/2)

Wayne Chang, Will Ripley and Eric Cheung, CNN

Tue, February 25, 2025 at 6:59 p.m. PST·5 min read

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: it has been quietly happening in the pharmaceutical sector.

In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug.

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the American behemoth that has dominated cancer treatment.

Patients treated with Akeso’s new drug went 11.1 months before their tumors began to grow again, compared with 5.8 months for Keytruda, according to clinical data released at the World Conference on Lung Cancer, a top medical forum.

Over the course of several days in early September, shares in California-based Summit Therapeutics, Akeso’s US partner, more than doubled to a record high, according to data from Refinitiv. The firm had licensed the right to commercialize the new drug in North America and Europe.

At the time, though experts said it was a watershed moment for Chinese pharmaceutical companies, it was little noticed outside the industry. All that changed following DeepSeek’s exploits earlier this year, which put international attention on pockets of innovation in China — with growing global implications.

“I do believe the Chinese biotech industry will play an important role globally. And we [will] participate more and more,” Michelle Xia, the CEO of Akeso, said in an interview last month with BiotechTV.

In a statement sent to CNN, Akeso said it was an “incredibly exciting moment” to see its drug beat Keytruda, the world’s best-selling medication.

“Akeso’s innovation is driven by a deep understanding of disease biology and protein engineering, while benefitting from the fast development time and the abundance of top-tier talent in China,” it said.

 

The rise of Chinese biotech

Until the 1980s, when China opened up its economy, most of its pharmaceutical firms were state-owned. For most of the past 40 years, Chinese biotech companies were mainly replicating existing medications, known as “me-too” drugs.

But over the past 10 years, they’ve begun to innovate with more advanced drugs that can compete directly with the Western offerings. And they’ve signed billions of dollars in licensing deals with Western partners to get their products to the rest of the world.

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh Pharmaceutical over an experimental weight loss pill.

“People were aware that the biotech industry was growing very fast in China, but very few saw it as a real threat to the top US innovators,” said Rebecca Liang, a pharmaceuticals analyst at AB Bernstein. “Now the threat is getting real, because you do start to see these next generation drugs that are sort of a leapfrog.”

(to be continued)

Translation

一家名不見經傳的中國公司研發出一種藥物,打敗了全球最暢銷的藥物(1/2)

中國的 DeepSeek 以令人難以置信的價格實現了意想不到的創新,震驚了世界。但這種顛覆性趨勢並不限於大型科技公司:它也已在製藥業悄悄發生。

9 月,康方生物 - 一家成立於近十年、名不見經傳的中國生物科技公司 - 憑藉其新型肺癌藥物震撼了生物科技界。

在中國進行的一項試驗發現,新藥 Ivonescimab 的效果優於Merck公司開發的暢銷藥物 Keytruda,後者為主導癌症治療市場的美國巨頭帶來了超過 1,300 億美元的銷售額。

根據在頂級醫學論壇世界肺癌大會上發布的臨床數據,使用康方新藥治療的患者的腫瘤在 11.1 個月後才開始再次生長,而使用 Keytruda 治療的患者的腫瘤在 5.8 個月後就開始再次生長。

根據 Refinitiv 的數據,9 月初的幾天內,康方生物美國合作夥伴加州 Summit Therapeutics 的股價上漲了一倍多,創下歷史新高。該公司已獲得在北美和歐洲銷售該新藥的權利。

當時,儘管專家表示,這是中國製藥公司的分水嶺,但業內外卻很少注意到。今年早些時候,DeepSeek 的探索讓一切都改變了,中國的其中一些團體的創新引起了國際社會的關注,其全球影響力也越來越大。

康方生物執行長Michelle Xia上個月在接受 BiotechTV 採訪時表示: 「我確實相信中國生物科技產業將在全球發揮重要作用。而且我們將會有更多參與」。

康方生物在發給 CNN 的聲明中表示,看到自己的藥物擊敗全球最暢銷藥物 Keytruda,是一個「無比令人興奮的時刻」。

該公司表示: “康方生物的創新是源於對疾病生物學和蛋白質工程的深刻理解,同時受益於中國快速的發展時間和豐富的頂尖人才。”

 

中國生物科技的崛起

直到1980年代中國實施經濟開放前,大多數製藥公司都是國營企業。在過去 40 年的大部分時間裡,中國生物科技公司主要在複製現有藥物,即所謂的「仿製藥」。

但在過去十年裡,他們開始創新,研發出更先進的藥物,可以直接與西方藥物競爭。他們還與西方合作夥伴簽署了價值數十億美元的授權協議,以將他們的產品推向世界其他地區。

去年,AstraZeneca 與中國石藥集團簽署了一項價值 19.2 億美元的協議,開發心血管藥物,而Merck則與中國豪森藥業簽署了一項價值 20 億美元的協議,共同開發一種實驗性減肥藥。

AB Bernstein 的製藥業分析師 Rebecca Liang 表示:“人們意識到中國生物技術產業發展非常迅速,但很少有人認為這對美國頂尖創新者構成了真正的威脅” ; “現在威脅已經變得真實,因為你確實開始看到這些下一代藥物具有蛙跳式的發展。”

(待續)

Note:

1.Akeso, Inc. (康方生物), established in 2012, is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. (https://www.akesobio.com/en/about-us/corporate-profile/)

2. A me-too drug (類似藥物)as defined as a pharmacologically active compound that is structurally related to a first-in-class compound, regarded as belonging to the same therapeutic class as the original compound, and used for the same therapeutic purposes, but which may differ in some respects, such as specificity of pharmacological action, adverse reactions profile, or drug-drug interactions. (https://pubmed.ncbi.nlm.nih.gov/32358800/#:~:text=We%20define%)

3. A "me-too drug" is a medication that is similar to a pre-existing drug, often with minor modifications, and acts on the same target as the first drug of its kind. This differs from a generic drug (仿製藥), which is a copy of a brand-name drug with the same active ingredients, dosage, and intended use.

2025年3月20日 星期四

初創公司 PsiQuantum 表示正在製造數百萬個量子計算晶片

 Recently Yahoo News on-line picked up the following:

Startup PsiQuantum says it is making millions of quantum computing chips

Reuters - Max A. Cherney and Stephen Nellis

Wed, February 26, 2025 at 8:45 a.m. PST·2 min read

SAN FRANCISCO (Reuters) - PsiQuantum said on Wednesday it had cracked one of the crucial challenges in quantum computing: a method to manufacture quantum chips at the volumes needed to build commercially viable machines.

Quantum technology has the potential to perform types of calculations that would stump even the most powerful artificial intelligence systems that use Nvidia chips and could unlock a host of scientific and commercial applications, including cybersecurity. The technology may help in drug discovery and in materials research.

But mass manufacturing of quantum computing chips has been a difficult problem to solve. Seeking a solution, PsiQuantum's founders decided almost 20 years ago to pursue an approach that could be made using photonics, the same semiconductor manufacturing technology widely used in the communications industry.

The company spent ensuing years working closely with chip factories to engineer its chipset, called Omega, which is now ready for production, PsiQuantum Chief Executive Jeremy O'Brien told Reuters in an interview on Tuesday.

"This isn't a breakthrough, this is actually something that has gone out of the research lab, and that is the highest level of maturity that you can achieve," O'Brien said, referring to bringing a quantum chip to mass production.

The company has partnered with GlobalFoundries to fabricate the chips at the latter's Albany, New York, factory.

PsiQuantum's method uses chip industry-standard foot-wide wafers on GlobalFoundries' 45-nanometer process and has achieved manufacturing yields that match standard semiconductors, according to PsiQuantum's Chief Scientific Officer Pete Shadboldt.

"We're right now making millions of them in GlobalFoundries," Shadboldt said.

PsiQuantum published findings related to the mass-manufacture of its Omega quantum chips in the scientific journal Nature on Wednesday.

The Palo Alto, California-based company's quantum computing technology manipulates particles of light, or photons, to perform the quantum calculations. The light-based approach has several advantages, such as deploying significantly less complex mechanisms needed to cool its quantum devices, according to O'Brien and Shadboldt.

O'Brien told Reuters in 2023 the company planned to target a commercial quantum computer within six years. He said on Tuesday in the interview the company expects to complete a facility with the ability to perform commercial applications by roughly 2027.

Last week, Microsoft showcased a quantum chip that took a different approach but said that it shows such computers are "years not decades" away. And after a significant breakthrough that Alphabet Inc's Google announced in December, the search company said earlier this month commercial applications could arrive within five years.

PsiQuantum said in 2023 it had a valuation of $3.15 billion.

Translation

初創公司 PsiQuantum 表示正在製造數百萬個量子計算晶片

(路透社)- PsiQuantum 週三表示,它已經破解了具有量子計算的一個關鍵挑戰:一種以製造商業上可行機器所需的數量來生產量子晶片的方法

量子技術有可能執行多種運算,這些運算甚至會難倒使用 Nvidia 晶片的最強大的人工智慧系統,並可以解除包括網路安全在內的一系列科學和商業應程式中的限制。該技術可能有助於藥物研發和材料研究。

但量子運算晶片的量產一直是個難以解決的難題。為了尋求解決方案,PsiQuantum 的創始人在近 20 年前就決定尋求一種可以使用光子學的方法,同樣半導體製造技術已在通訊產業中廣泛應用。

PsiQuantum 執行長 Jeremy O'Brien 週二接受路透社採訪時表示,該公司隨後幾年與晶片工廠密切合作,設計出名為 Omega 的晶片組,目前已準備好投入生產。

O'Brien 在談到量子晶片的量產時表示: “這並不是什麼突破,實際上這只是走出實驗室的研究成果,也是目前可以達到的最高成熟度。”

該公司已與 GlobalFoundries 合作,在後者位於紐約州Albany的工廠去生產晶片。

PsiQuantum 首席科學官 Pete Shadboldt 表示,PsiQuantum 的方法是在 GobalFoundries 45納米的工藝上使用芯片行業標準的英尺寬晶圓,並實現了與標準半導體相匹配的製造產量。

Shadboldt 表示: “我們目前在 GlobalFoundries 的生產量是數以百萬計。”

PsiQuantum 週三在科學期刊《自然》上發表了有關其 Omega 量子晶片量產的研究結論。

這家總部位於加州的 Palo Alto公司的量子計算技術,可以操縱光粒子或光子來進行量子計算。據O'Brien 和 Shadboldt 表示,基於光的方法有幾個優點,例如部署去冷卻量子設備所需的機制要簡單得多。

O'Brien 在 2023 年向路透社透露,該公司計劃六年內推出商用量子電腦。他在周二的採訪中表示,該公司預計將在 2027 年左右建成一座能夠進行商業應用的設施。

上週,微軟展示了一款採用不同方法的量子晶片,但它表明這種電腦的誕生還需要「幾年而不是幾十年」的時間。繼 Alphabet Inc 旗下的谷歌於 12 月宣布重大突破後,這搜尋公司本月稍早表示,商業應用可能會在五年內到來。

PsiQuantum 在2023 年表示,其估值為 31.5 億美元。

       So, PsiQuantum says that it has cracked one of the crucial challenges in quantum computing: a method to manufacture quantum chips at the volumes needed to build commercially viable machines. I am wondering how this will impact on the manufacturing of quantum computers.

2025年1月3日 星期五

The secret of the bacteria's ability to withstand radiation that exceeds the lethal dose for humans is revealed

Recently CNN.co.jp reported the following:

人間の致死量超える放射線に耐えられる細菌、能力の秘密が明らかに

2024.12.12 Thu posted at 18:28 JST

(CNN) 「デイノコッカス・ラジオデュランス」と呼ばれる細菌の一種は最も過酷な環境でも生き延びる能力を持つ。「英雄コナン」にちなみ「コナン・ザ・バクテリア」というニックネームが付けられており、人間の致死量の2万8000倍もの放射線に耐えられる。今回、その能力の秘密が抗酸化物質にあることが分かった。

科学者は抗酸化物質の働きを解明し、地球上の人間と将来地球外を探索する人々の健康を守るために抗酸化物質を利用できる可能性を解き明かした。

抗酸化物質はマンガン、リン酸塩、アミノ酸のペプチド(分子)を含む代謝産物と呼ばれる小さな分子の単純な集合体で構成されている。

米国科学アカデミー紀要に9日に発表された研究で、この強力な三つの成分を組み合わせると、マンガンと他の成分の一つのみを組み合わせた場合よりも放射線に対する防御効果が高いことが明らかになった。

研究の著者らによると、この発見は、将来太陽系を横断する深宇宙ミッションで宇宙飛行士を高線量の宇宙放射線から守るために活用できる可能性がある。

 

抗酸化物質の秘密を解明

デイノコッカスは最も放射線耐性が高い生物としてギネス世界記録に登録されている。これまでの研究で、この細菌は国際宇宙ステーション(ISS)の外で3年生存できることがわかっている。酸や寒さ、脱水状態にも耐えられる。

2022年10月の報告によれば、デイノコッカスが火星に存在していた場合、凍結した状態で何百万年も生き延びていた可能性があるという。

以前、細菌の細胞内のマンガン抗酸化物質の量を測定したところ、微生物が生き延びることができる放射線の量はマンガン抗酸化物質の量に直接関係していることがわかった。つまり、マンガン抗酸化物質が多いほど、放射線への耐性が増す。

乾燥して凍結すると、デイノコッカスは14万グレイに耐えられる。これは人間の致死量にあたる放射線量の2万8000倍だ。

今回の研究では、デイノコッカスにヒントを得て設計された合成抗酸化物質、MDP(メラトニン由来の保護物質)を使用した。

研究チームは、マンガン、リン酸塩、DP1と呼ばれるペプチドを含むMDPの活性成分が、細胞やたんぱく質を放射線被ばくからどのように保護するかを分析。ペプチドとリン酸塩がマンガンに結合すると、放射線に対する保護にきわめて効果的な三元複合体が形成される。

ユニフォームド・サービス大学の病理学教授であるマイケル・デイリー氏は「MDPに関する今回の新たな理解はさらに強力なマンガンベースの抗酸化剤の開発につながる可能性がある。これは医療や製造業のほか防衛、宇宙探査に応用しうる」と述べた。

また、「MDPは単純で費用対効果が高いうえ、無毒で非常に効果的な放射線防護剤であるため、経口投与することで宇宙放射線のリスクを軽減できる可能性がある」とも指摘する。

地球上では、放射線の漏えい事故に対する保護に使用することも考えられる。

Translation

The secret of the bacteria's ability to withstand radiation that exceeds the lethal dose for humans is revealed

 (CNN) A type of bacteria called "Deinococcus radiodurans" had the ability to survive even in the harshest environments. It was nicknamed "Conan the Bacteria" after the "Hero Conan" series, it could withstand radiation that was 28,000 times the lethal dose for humans. Now, it had been discovered that the secret of its ability lay in antioxidants.

Scientists had uncovered how antioxidants work and revealed the possibility of using them to protect the health of humans on Earth and those who might explore extraterrestrials in the future.

Antioxidants were made up of simple aggregates of small molecules called metabolites that contained manganese, phosphate, and peptides (molecules) of amino acids.

A study published in the Proceedings of the National Academy of Sciences of the United States of America on the 9th revealed that the combination of this powerful trio of ingredients provided more protection against radiation than manganese combined with one of the other ingredients alone.

According to the study authors, this discovery could be used to protect astronauts from high doses of space radiation on future deep space missions across the solar system.

Unlocking the secrets of antioxidants

Deinococcus is listed in the Guinness World Records as the most radiation-resistant organism. Studies so far had shown that the bacterium could survive for three years outside the International Space Station (ISS). It could also withstand acid, cold, and dehydration.

According to a report in October 2022, if Deinococcus existed on Mars, it could have survived for millions of years in a frozen state.

Previously, when the amount of manganese antioxidants in the bacterial cells was measured, it was found that the amount of radiation that the microorganism could survive is directly related to the amount of manganese antioxidants. In other words, the more manganese antioxidants there were, the more resistant it was to radiation.

When dried and frozen, Deinococcus could withstand 140,000 grays, which was 28,000 times the amount of radiation that would be lethal to human.

In this study, a synthetic antioxidant, MDP (Melatonin-derived Protective Protein) was used, it was designed with Deinococcus as inspiration.

The research team analyzed how the active components of MDP, which contained manganese, phosphate, and a peptide called DP1, had protected cells and proteins from radiation exposure. When the peptide and phosphate bound to manganese, they formed a ternary complex that was highly effective at protecting against radiation.

Michael Daly, professor of pathology at the Uniformed Services University said that "This new understanding of MDP could lead to the development of even more powerful manganese-based antioxidants, it could have applications in medicine, manufacturing, defense, and space exploration."

He also noted that "MDP is a simple, cost-effective, non-toxic, and highly effective radioprotector, which could potentially reduce the risks of space radiation when administered orally."

On Earth, it could also be used to protect against accidental radiation leaks.

              So, a type of bacteria called "Deinococcus radiodurans" has the ability to survive even in the harshest environments. A research team analyzed how the active components of MDP, which contain manganese, phosphate, and a peptide can protected cells and proteins from radiation exposure. It is also noted that MDP is a simple, cost-effective, non-toxic, and highly effective radioprotector. On Earth, it could also be used to protect against accidental radiation leaks. Apparently, MDP will help us in our space exploration projects.

Note:

1. Proceedings of the National Academy of Sciences of the United States of America (PNAS) is a peer-reviewed multidisciplinary scientific journal. It is the official journal of the National Academy of Sciences, published since 1915, publishing original research, scientific reviews, commentaries, and letters. (Wikipedia)

2. A gray (Gy) is the SI-derived unit of absorbed dose and specific energy (energy per unit mass). Such energies are usually associated with ionizing radiation such as gamma particles or X-rays. It is defined as the absorption of one joule of energy in the form of ionizing radiation by one kilogram of tissue. In the SI basic units, a gray is expressed as m²⋅s⁻².(https://www.translatorscafe.com/unit-converter/en-US/radiation-absorbed-dose/7-1/gray-rad/)

2024年9月29日 星期日

平治車廠與 Factorial 合作開發固態電池

Recently Yahoo News on-line picked up the following:

Mercedes teams up with Factorial to develop solid-state batteries

Nick Carey

Tue, September 10, 2024 at 5:06 a.m. PDT·2 min read

LONDON (Reuters) - Mercedes-Benz and U.S. battery startup Factorial are working on a solid-state battery that should dramatically increase electric vehicle range and be ready for production by the end of the decade, the companies said on Tuesday.

The new battery, dubbed Solstice, should extend EV range about 80% above today's average, with an energy density of 450 Watt-hours per kilogram, the companies said in a statement.

Solid-state batteries have been billed as a game-changing technology for EVs, as they should reduce fire risk and allow for lighter, lower-cost cars than can travel further on a single charge.

But they have proven harder than expected for major automakers and battery making partners to develop at scale.

Auto groups are urgently seeking ways to cut costs and boost EV range as sales have stagnated in Europe in particular.

Factorial has already developed a quasi-solid-state battery that automakers including Mercedes are testing and should be in EVs on the road in 2026.

Mercedes has invested in Factorial, which raised $200 million in 2022, alongside rivals Stellantis and Hyundai.

Factorial developed quasi-solid-state batteries first because they can use similar production lines to conventional lithium-ion batteries, meaning they can scale up faster, CEO Siyu Huang told Reuters.

In a solid-state battery, the liquid electrolyte through which the electrical charge passes should be replaced with a solid substitute, reducing fire risk and shrinking battery pack size.

Huang said that solid-state batteries would not require expensive, heavy cooling systems needed for today's battery packs, allowing automakers to further reduce costs.

"We're not just focused on the cost of (battery) cell, but the cost of the overall vehicle," she said.

The challenges of developing solid-state batteries include poor performance in cold weather and the battery pack's tendency to expand.

Mercedes Chief Technology Officer Markus Schaefer told Reuters that Factorial's solid-state batteries could provide a 40% improvement in energy density over the German premium automaker's high performance batteries today.

This would enable Mercedes to either significantly reduce EV battery pack size - batteries are an EV's most expensive and heaviest component - or provide long-range electric cars for those who want them.

He added that lighter batteries would allow Mercedes to use steel for EV bodies instead of far more expensive and carbon intensive high-strength aluminum.

Mercedes is also working with Taiwanese battery maker ProLogium, in which it has invested, on solid-state batteries and is researching high-silicon anodes as an alternative solution to increase EV battery density.

 "There are some challenges that you have to get under control, but ... we have great engineering solutions to address them," Schaefer said, adding that he believed Factorial's goal of developing Solstice at scale by the end of the decade was realistic.

 (Reporting by Nick Carey; Editing by Mark Potter)

Translation

倫敦(路透社)—平治和美國電池新創公司Factorial 週二表示,它們正在開發一種固態電池,這種電池將大幅增加電動車的續航里程,並在本世紀二十年代末之前準備好投入生產。

兩家公司在聲明中表示,這款名為 Solstice 的新型電池將使電動車的續航里程比目前的平均水平提高約 80%,能量密度為每公斤 450 瓦時。

固態電池被認為是電動車的改變遊戲規則的技術,因為它們可以降低火災風險,並允許汽車更輕、成本更低,一次充電可以行駛更遠的距離。

但事實證明,對於主要汽車製造商和電池製造合作夥伴來說,大規模開發比預期更加困難。

由於歐洲的銷售停滯不前,汽車集團正在緊急尋求削減成本和提高電動車續航里程的方法。

Factorial 已經開發出一種準固態電池,包括平治在內的汽車製造商正在測試該電池,預計將於 2026 年應用於電動車。 

平治向Factorial投資, 在2022年它集資了2 億美元,與該公司一起競爭的對手包括 Stellantis 和現代。

Factorial執行長Siyu Huang告訴路透社,他們首先開發了準固態電池,因為這生產線可以使用於傳統鋰離子電池類,這意味著它們可以更快地擴大規模。

在固態電池中,被電荷通過的液體電解質會被替換為固體替代品,以降低火災風險並縮小電池組尺寸。

Huang說,固態電池不需要當今電池組所需的昂貴、重型冷卻系統,使汽車製造商能夠進一步降低成本。

她說:「我們不僅關注(電池)電的成本,還關注整部車的成本」。

開發固態電池面臨的挑戰包括寒冷天氣下的性能不佳以及電池組容易膨脹。

平治首席技術長 Markus Schaefer 告訴路透社,與這家德國高端汽車製造商目前的高性能電池相比,Factial 的固態電池可將能量密度提高 40%。

這將使平治能夠顯著減小電動車電池組的尺寸(電池是電動車最昂貴和最重的部件),可為有需要的人提供遠程電動車。

他補充說,更輕的電池將使平治能夠在電動車身上使用鋼,而不是更昂貴且碳密集的高強度鋁。

平治也與其投資的台灣電池製造商ProLogium合作開發固態電池,並正在研究高矽陽極, 作為提高電動車電池密度的替代解決方案。

Schaefer 表示:「有些挑戰必須得到控制,但…我們有出色的工程解決方案來處理這些挑戰。」他補充說,他相信 Factorial 在本世紀二十年代末之前去大規模開發 Solstice 的目標是可實現的。

              So, Mercedes-Benz and U.S. battery startup Factorial are working on a solid-state battery that could dramatically increase electric vehicle range and be ready for production by the end of the decade. If they are successful, they will revolutionize the making of EVs.